(Reuters) – Drug developer Oyster Point Pharma Inc said on Monday the U.S. Food and Drug Administration had approved its nasal spray for treatment of dry eye disease.
(Reporting by Leroy Leo and Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
